The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models

Samankaltaisia teoksia

• DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
  Tekijä: LaBonte, Melissa J, et al.
  Julkaistu: (2009)
• Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
  Tekijä: Collantes Maria, et al.
  Julkaistu: (2010-05-01)
• Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
  Tekijä: Diaz, Roque, et al.
  Julkaistu: (2010)
• The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer
  Tekijä: LaBonte, M. J., et al.
  Julkaistu: (2012)
• Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
  Tekijä: Kim, Hwang-Phill, et al.
  Julkaistu: (2009)